P516: Efficacy and safety of tofacitinib retreatment for ulcerative colitis after treatment interruption: Results from the OCTAVE clinical trialsECCO '18 Vienna
2018
P518: Vedolizumab trough concentrations are associated with endoscopic response in patients with inflammatory bowel diseaseECCO '18 Vienna
2018
P519: Switching from reference infliximab to CT-P13 in patients with inflammatory bowel disease: Multicentre study at 12 months resultsECCO '18 Vienna
2018
P520: Gastrointestinal ultrasonography in pregnant patients with IBD is useful in the identification of active intestinal inflammationECCO '18 Vienna
2018
P521: Evaluation of adalimumab effectiveness in paediatric patients with ulcerative colitis in clinical practiceECCO '18 Vienna
2018
P522: Soluble sMadCAM1 and retinoic acid are potential tools for therapeutic drug monitoring in inflammatory bowel disease s under vedolizumab: A proof of conceptECCO '18 Vienna
2018
P523: New guidance on therapeutic drug monitoring; potential clinical and cost implicationECCO '18 Vienna
2018
P524: Active smoking and personal concerns about treatment can impair adherence to adalimumab in inflammatory bowel diseases: A prospective evaluationECCO '18 Vienna
2018
P525: Adherence and persistence with vedolizumab among patients with inflammatory bowel disease in an academic medical centreECCO '18 Vienna
2018
P526: Early sonographic response predicts long-term outcome in Crohn’s disease: A prospective cohort studyECCO '18 Vienna
2018
P527: Low adalimumab serum levels at Week 4 provoke immunogenicity and influence therapy outcome in anti-TNF naïve Crohn’s disease patientsECCO '18 Vienna
2018
P529: Longer duration of vancomycin prevents recurrence of C. difficile in patients with inflammatory bowel diseaseECCO '18 Vienna
2018
P530: Psychosexual dysfunction in Greek patients with inflammatory bowel disease in remissionECCO '18 Vienna
2018
P531: Tuberculin skin test conversion rate in inflammatory bowel disease patients receiving anti-TNFα agentsECCO '18 Vienna
2018
P532: Efficacy of combination therapy with cyclosporin and vedolizumab in inflammatory bowel diseases refractory to anti-TNF agentsECCO '18 Vienna
2018
P533: Correlation of endoscopic and clinical endpoints during induction therapy in patients with moderate-to-severe Crohn’s disease: Analysis from CELEST studyECCO '18 Vienna
2018